Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia
The Efficacy and Safety of Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Tianjin
-
Tianjin, Tianjin, China, 300041
- Recruiting
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
-
Contact:
- Erlie Jiang
- Phone Number: +86-15122538106
- Email: jiangerlie@ihcmas.ac.cn
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Ages 16-65 years inclusive.
- Diagnosed as acute leukemia, planning to receive haplo-HSCT
- Eastern Cooperative Oncology Group (ECOG) Performance status 0-2
- Presence of an available haploidentical donor
- Signing written informed consent and agreeing with taking designated umbilical cord blood
Exclusion Criteria:
- Uncontrolled infections less than 4 weeks prior to enrollment
- Secondary malignancy
- Psychiatric illness that would limit compliance with study requirements
- Impairment of heart, hepatic or renal function to such an extent that the patient, in the opinion of the investigator, will be exposed to an excessive risk if entered into this clinical study
- Allergic to blood products
- Other causes which are not suitable for the trial in investigator's consideration
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Haplo-HSCT group
58 patients will be involved in this group
|
Receive haploidentical hematopoietic stem cell transplantation (HLA 6-10/10)
|
|
Experimental: Combined haploidentical and umbilical cord blood allogeneic stem cell transplantation group
58 patients will be involved in this group
|
Patients will receive umbilical cord blood allogeneic stem cell transplantation at the same day as the haploidentical stem cell transplantation.
(HLA 6-10/10, TNC≥1-3×10-7/Kg)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall survival
Time Frame: 12 months
|
Defined as the survival duration starting at the day of transplantation, terminating at the day of death or the end of follow-up
|
12 months
|
|
Disease free survival
Time Frame: 12 months
|
Defined as the time starting at the day of transplantation, terminating at the day when the sign of AL is found or the end of follow-up
|
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cumulative relapse incidence
Time Frame: 12 months
|
Defined as the cumulative incidence of relapse after the day of transplantation
|
12 months
|
|
Cumulative incidence of engraftment
Time Frame: 12 months
|
Neutrophil recovery was defined as an absolute neutrophil count(ANC) of 0.5×10^9/L or more for three consecutive days , while platelet recovery difined as 20×10^9/L or more for seven consecutive days without transfusion
|
12 months
|
|
cumulative incidence of acute graft-versus-host disease(GVHD)
Time Frame: 12 months
|
Acute graft versus host disease will be diagnosed and graded by modified Glucksberg criteria
|
12 months
|
|
cumulative incidence of chronic GVHD at one year
Time Frame: 12 months
|
chronic graft versus host disease will be diagnosed and graded by National Institute of Health Consensus (NIH Consensus)
|
12 months
|
|
Cumulative Incidence of Infectious Complications
Time Frame: 12 months
|
Defined as cumulative incidence of viral, fungal and bacterial infections
|
12 months
|
|
Cumulative Incidence of hemorrhagic cystitis
Time Frame: 12 months
|
Defined as the cumulative incidence of hemorrhagic cystitis after the day of transplantation
|
12 months
|
|
Cumulative Incidence of lymphoproliferative disease
Time Frame: 12 months
|
Defined as the cumulative incidence of lymphoproliferative disease after the day of transplantation
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 20220410
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.